계명대학교 의학도서관 Repository

Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis

Metadata Downloads
Author(s)
See Hyung KimMi Sun ChoiMi Jung KimYoung Hwan KimSeung Hyun Cho
Keimyung Author(s)
Choe, Mi SunKim, Mi JeongKim, See HyungKim, Young Hwan
Department
Dept. of Pathology (병리학)
Dept. of Radiology (영상의학)
Journal Title
American Journal of Roentgenology
Issued Date
2017
Volume
209
Issue
4
Keyword
Prostate Imaging Reporting and Data System (PI-RADS) version 2multiparametric MRIprostate cancer
Abstract
OBJECTIVE:
The purpose of our study was to prospectively assess Prostate Imaging Reporting and Data System (PI-RADS) version 2 using an MRI-ultrasound fusion biopsy.

SUBJECTS AND METHODS:
This study included 295 consecutive patients with 478 lesions who underwent multiparametric MRI and subsequent MRI-ultrasound fusion biopsy between December 2014 and September 2016. Lesions were assessed by using an overall score of PI-RADS version 2. One radiologist assessed the presence or absence of clinically significant prostate cancer in the whole gland and in subgroups of the peripheral zone and transition zone by using cutoff values of ≥ 4 and ≥ 3. Histologic examination of MRI-ultrasound fusion biopsy specimens was used as the reference standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated to assess the utility of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer.

RESULTS:
The overall PI-RADS version 2 scores showed an accuracy of 82.2% (393/478) for the whole gland, with a cutoff value of ≥ 4 granting sensitivity of 90.0% (90/100), specificity of 80.1% (303/378), PPV of 83.3% (90/108), and NPV of 81.8% (303/370). The overall scores showed accuracies of 84.7% (301/355) in the peripheral zone and 74.7% (92/123) in the transition zone. When we applied an arbitrary overall score of ≥ 3, accuracy was 68.6% (328/478), sensitivity was 94.6% (124/131), specificity was 58.7% (204/347), PPV was 51.6% (124/240), and NPV was 85.7% (204/238).

CONCLUSION:
PI-RADS version 2 has an overall good performance for the diagnosis of clinically significant prostate cancer.
Keimyung Author(s)(Kor)
최미선
김미정
김시형
김영환
Publisher
School of Medicine (의과대학)
Citation
See Hyung Kim et al. (2017). Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis. American Journal of Roentgenology, 209(4), 800–805. doi: 10.2214/AJR.16.17629
Type
Article
ISSN
0361-803X
Source
https://www.ajronline.org/doi/full/10.2214/AJR.16.17629
DOI
10.2214/AJR.16.17629
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41572
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Pathology (병리학)
1. School of Medicine (의과대학) > Dept. of Radiology (영상의학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.